President of Bayer prescription drugs in China: 13 billion sales in China in 2016

On April 11, Bayer Group announced its performance in China in 2016: 1.8 billion euros (more than 13 billion yuan in total) For many years in a row, Bayer Group's prescription drug business has been developing strongly in China Since 2015, the year-on-year growth of 7%, the year-on-year growth of sales of prescription drugs in China in 2016 has reached 10% Bayer is one of the few multinational pharmaceutical companies that will disclose the sales volume of China alone, which is directly related to the position of China in Bayer's global overall sales market; at the beginning of the 21st century, Bayer also once ranked first in the list of multinational pharmaceutical companies' sales of prescription drugs in China On April 11, 2017, Jiang Wei, President of Bayer prescription medicine business in China, attended Bayer prescription medicine China press conference in Beijing and reported the sales performance of Bayer Group's prescription medicine business in China in 2016 This is the second time Jiang Wei has participated in this activity since he became executive vice president of Bayer prescription medicine business division in China and Asia Pacific since October 1, 2015 Compared with the sales volume of about RMB 11.4 billion in 2015, Bayer's prescription drug business increased by 10% in 2016, reaching about RMB 13 billion Jiang Wei regards "wide distribution" and "innovative medicine" as two strategic elements for the success of pharmaceutical enterprises In Jiang Wei's view, the reason why Bayer's prescription drugs can maintain a steady growth in China is still the same as last year's statement, that is, Bayer's continuous investment in the field of chronic disease management and innovation in research and development of innovative products, "and 2017 is estimated to be the two reasons." Jiang Wei laughs Figure: Jiangwei 1 is optimistic about the blue ocean of innovative drugs Since March, Bayer has received continuous good news in the prescription drug business First, sorafenib, an oral multi kinase inhibitor for the treatment of a differentiated thyroid cancer, was approved by CFDA after the priority review, and then two new indications, i.e regofinib, an oral multi kinase inhibitor, for metastatic colorectal cancer and gastrointestinal stromal tumor, were approved at the same time The approval of new drugs and new indications reflects Bayer's attention to innovative drugs "We don't think what we are facing is a red sea of price, but what we are seeing is a blue sea of high-quality innovative drugs." In an interview, Jiang Wei said that innovation is the soul of pharmaceutical enterprises At present, the introduction of many policies in China's pharmaceutical environment, to a certain extent, plays a role in promoting the development and introduction of Bayer's innovative drugs The most direct boost to Bayer's current business in China is the decision on adjusting matters related to the registration and management of imported drugs (Draft for comments), also published by CFDA in March According to the draft, in the future import drug registration process, after the completion of the international multi center, it can directly apply for drug listing registration Lang Zhihui, vice president of Bayer's prescription medicine China Medical Department, told e drug managers that the policy will help Bayer introduce more innovative drugs to China faster "In the past, there was a gap of 4 to 6 years between the time when new drugs were put on the market at home and abroad, and now such a gap will be gradually shortened to the final elimination." Lang Zhihui revealed that Bayer's products in the later stage of development will benefit directly from this At the same time, the introduction of the new policy will also more effectively promote synchronous research and development at home and abroad "Before, the R & D process was completed in phase I and phase II clinical practice abroad, and phase III clinical practice was carried out in China Sometimes, more data needs to be filled because of insufficient data If phase I clinical practice can be carried out in China, Chinese patients are expected to use the most cutting-edge drugs in the world at the same time with patients in the United States and other countries, which will be a great benefit for patients " Lang Zhihui said that China's R & D center in Beijing is ready to support the implementation of the policy Jiang Wei said that the positioning of China's R & D center is also in the process of integrating local research into global R & D on the one hand, Bayer pays more attention to how to localize foreign data in China, but on the other hand, it also pays attention to how to internationalize China's data, and a series of reforms brought about by CFDA can make China more quickly integrate into the global R & D of new drugs According to the data provided by Bayer, in 2016, Bayer's R & D investment in the world increased by 9.8% to 4.7 billion euros, of which about 60% of the R & D investment (about 2.8 billion euros) was used in the field of prescription drugs, with research and development focusing on cardiovascular diseases, tumors and women's health In 2017, Bayer's planned investment in R & D will increase to 4.8 billion euros Thanks to the continuous investment in R & D innovation, Bayer has a rich R & D product line for prescription drugs A total of more than 50 compounds are undergoing phase I to III clinical trials in response to many urgent medical needs Among them, six compounds in the middle and later stages of research and development are expected to be used to treat multiple types of cancer, diabetic nephropathy, chronic heart failure, uterine leiomyoma and other diseases with high incidence in China and even the whole Asia Pacific region The total annual sales of these products are expected to reach at least 6 billion euros in the future At the price level, Jiang Wei expressed support and support for the price negotiation policy of the original research drug currently being implemented in China In terms of drug accessibility, the first is to ensure the progress of scientific research, the second is to ensure the high quality of products and the third is to ensure the interests of employees Jiang Wei said that under these three premises, Bayer has a flexible attitude towards anything in fact, and will find ways to do what should be done and what can be done At present, Bayer's prescription medicine business has covered cardiovascular disease, cancer, diabetes, women's health, multiple sclerosis and other fields, but in the market, the most outstanding performance is still its chronic disease-related products At present, more than 260 million chronic disease patients have been confirmed in China, and Bayer's chronic disease products such as aspirin, betaine and betazepine are playing a role in the prevention and treatment of major chronic diseases such as cardiovascular disease and diabetes In addition, as a new type of oral anticoagulant, bairuituo also provides simple anticoagulant treatment options for Chinese patients in the two fields of arteriovenous thrombosis In addition, Bayer has also launched a series of innovative health management solutions and treatment concepts For example, like "big sugar medicine", an intelligent diabetes management cloud platform operator, has launched "power +" Chinese postprandial glucose optimization management platform Although there are many diabetes management software in the current mobile medical market and even the situation of "sugar wars", Jiang Wei also has a clear understanding of how to stand out in the fierce competition "Bayer's advantage is our unique understanding of the Chinese market in diabetes." In Jiang Wei's view, the strong brand of Bai Tangping in China, as well as Bayer's coverage and investment in China in the field of diabetes, as well as the large number of users accumulated by Bai Tangping, all contribute to the future development of Bayer's diabetes brand in the whole field In 2017, it was also the 10th anniversary of the launch of the "entering the west" health talent training project jointly carried out by the national health and Family Planning Commission (the former Ministry of Health) and Bayer Since 2007, the project has trained more than 35000 doctors and health management personnel in 26 provinces and regions Jiang Wei said that the project will continue to be carried out to further strengthen support for the training of grassroots health personnel.